Přihlásit se Zaregistrujte se zdarma

Hrubá marže společnosti Kazia Therapeutics

Jaká je hodnota metriky Hrubá marže společnosti Kazia Therapeutics?

Hodnota metriky Hrubá marže společnosti Kazia Therapeutics Limited je 100.00%

Jaká je definice metriky Hrubá marže?



Hrubá marže (Gross margin) je rozdíl mezi příjmy a náklady na prodané zboží dělený příjmy a vyjádřený v procentech.

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Hrubá marže společností v sektoru Health Care sektor na ASX ve srovnání se společností Kazia Therapeutics

Čemu se věnuje společnost Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Firmy s metrikou hrubá marže podobnou společnosti Kazia Therapeutics